ES2084361T3 - Derivados de quinuclidina. - Google Patents

Derivados de quinuclidina.

Info

Publication number
ES2084361T3
ES2084361T3 ES92912601T ES92912601T ES2084361T3 ES 2084361 T3 ES2084361 T3 ES 2084361T3 ES 92912601 T ES92912601 T ES 92912601T ES 92912601 T ES92912601 T ES 92912601T ES 2084361 T3 ES2084361 T3 ES 2084361T3
Authority
ES
Spain
Prior art keywords
compounds
disorders
quinuclidine derivatives
grastrointestinal
methoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912601T
Other languages
English (en)
Spanish (es)
Inventor
Fumitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
John Adams Lowe Iii
Terry Jay Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2084361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2084361T3 publication Critical patent/ES2084361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES92912601T 1991-05-31 1992-04-28 Derivados de quinuclidina. Expired - Lifetime ES2084361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31

Publications (1)

Publication Number Publication Date
ES2084361T3 true ES2084361T3 (es) 1996-05-01

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912601T Expired - Lifetime ES2084361T3 (es) 1991-05-31 1992-04-28 Derivados de quinuclidina.

Country Status (41)

Country Link
US (3) US5807867A (enExample)
EP (1) EP0587723B1 (enExample)
JP (2) JPH0733386B2 (enExample)
KR (1) KR100214905B1 (enExample)
CN (1) CN1048492C (enExample)
AP (1) AP299A (enExample)
AT (1) ATE135006T1 (enExample)
AU (1) AU657552B2 (enExample)
BG (1) BG61694B1 (enExample)
BR (1) BR9206073A (enExample)
CA (1) CA2102179C (enExample)
CZ (1) CZ281403B6 (enExample)
DE (4) DE9290063U1 (enExample)
DK (1) DK0587723T3 (enExample)
EG (1) EG19944A (enExample)
ES (1) ES2084361T3 (enExample)
FI (1) FI114475B (enExample)
GR (1) GR3019687T3 (enExample)
GT (1) GT199200028A (enExample)
HU (1) HU217548B (enExample)
IE (1) IE72473B1 (enExample)
IL (1) IL102008A (enExample)
IS (1) IS1611B (enExample)
LU (1) LU91293I2 (enExample)
MA (1) MA22539A1 (enExample)
MX (1) MX9202554A (enExample)
NL (1) NL300250I2 (enExample)
NO (2) NO302701B1 (enExample)
NZ (2) NZ270673A (enExample)
OA (1) OA09867A (enExample)
PL (1) PL171379B1 (enExample)
PT (1) PT100546B (enExample)
RO (1) RO110499B1 (enExample)
RU (1) RU2103269C1 (enExample)
SK (1) SK278788B6 (enExample)
TW (1) TW204349B (enExample)
UA (1) UA27776C2 (enExample)
UY (1) UY23422A1 (enExample)
WO (1) WO1992021677A1 (enExample)
YU (1) YU48995B (enExample)
ZA (1) ZA923942B (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
JP2909214B2 (ja) * 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
NZ254604A (en) * 1992-11-12 1997-06-24 Pfizer Quinuclidine derivative and pharmaceutical compositions thereof
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists to inhibit angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
IL136950A0 (en) * 1998-03-19 2001-06-14 Takeda Chemical Industries Ltd Heterocyclic compounds, their production and use
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
NZ569331A (en) * 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
WO2005043153A1 (en) * 2003-10-27 2005-05-12 Meyer Donald W Transmissible spongiform encephalopathy detection in cervids, sheep and goats
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
BRPI0507325A (pt) * 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ES2147889T3 (es) * 1996-01-19 2000-10-01 Lonza Ag Metodo para preparar 3-hidroxiquinuclidinol opticamente activo.
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
CN1048492C (zh) 2000-01-19
US5939433A (en) 1999-08-17
BG61694B1 (bg) 1998-03-31
JP2645225B2 (ja) 1997-08-25
ZA923942B (en) 1993-11-29
HUT70151A (en) 1995-09-28
HU217548B (hu) 2000-02-28
IS1611B (is) 1996-10-18
GT199200028A (es) 1993-11-20
US6222038B1 (en) 2001-04-24
US5807867A (en) 1998-09-15
IS3871A (is) 1992-12-02
DE69208877T2 (de) 1996-07-25
AP299A (en) 1994-01-14
PT100546B (pt) 1999-12-31
PT100546A (pt) 1993-08-31
IE921729A1 (en) 1992-12-02
IE72473B1 (en) 1997-04-23
YU56492A (sh) 1995-03-27
JPH06504292A (ja) 1994-05-19
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
NL300250I2 (nl) 2007-03-01
RO110499B1 (ro) 1996-01-30
KR100214905B1 (ko) 1999-08-02
FI935297A0 (fi) 1993-11-29
GR3019687T3 (en) 1996-07-31
MX9202554A (es) 1992-11-01
NL300250I1 (nl) 2007-02-01
CZ281403B6 (cs) 1996-09-11
RU2103269C1 (ru) 1998-01-27
IL102008A (en) 1995-12-08
PL171379B1 (en) 1997-04-30
ATE135006T1 (de) 1996-03-15
DE122006000066I2 (de) 2007-12-06
UY23422A1 (es) 1992-11-12
NO2007003I2 (no) 2011-04-18
DE9290063U1 (de) 1994-02-24
EP0587723A1 (en) 1994-03-23
EG19944A (en) 1997-02-27
CA2102179A1 (en) 1992-12-01
NO934312D0 (no) 1993-11-29
HU9303393D0 (en) 1994-03-28
TW204349B (enExample) 1993-04-21
FI935297L (fi) 1993-11-29
YU48995B (sh) 2003-04-30
WO1992021677A1 (en) 1992-12-10
JPH07285965A (ja) 1995-10-31
DE69208877D1 (de) 1996-04-11
FI114475B (fi) 2004-10-29
NZ242956A (en) 1995-06-27
BR9206073A (pt) 1994-12-06
SK390692A3 (en) 1998-02-04
AU657552B2 (en) 1995-03-16
SK278788B6 (sk) 1998-02-04
CA2102179C (en) 1998-10-27
BG98248A (bg) 1994-07-29
NO302701B1 (no) 1998-04-14
MA22539A1 (fr) 1992-12-31
JPH0733386B2 (ja) 1995-04-12
AP9200384A0 (en) 1992-07-31
IL102008A0 (en) 1992-12-30
NO934312L (no) 1993-11-29
CN1067428A (zh) 1992-12-30
AU1990192A (en) 1993-01-08
CZ390692A3 (en) 1994-02-16
NZ270673A (en) 1997-07-27
EP0587723B1 (en) 1996-03-06
NO2007003I1 (no) 2007-03-26
DE122006000066I1 (de) 2007-03-22
DK0587723T3 (da) 1996-04-01
UA27776C2 (uk) 2000-10-16

Similar Documents

Publication Publication Date Title
ES2065691T3 (es) Derivados de quinuclidina.
CA2102179A1 (en) Quinuclidine derivatives
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
ATE211743T1 (de) Substituierte 3-aminochinuclidine
NO176356C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
CA2121230A1 (en) 1,3-dihydro-2h-imidazo(4,5-b) quinolin-2-one derivatives
ES2157224T3 (es) Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
NO152902C (no) Analogifremgangsmaae for fremstilling av terapeutisk virksomme 1-alkyl-2-aminotetralinderivater
ATE25682T1 (de) Indol-3-carboxamid-derivate.
NO942952D0 (no) 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike
NO940523D0 (no) Nye pyrazin-derivater
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
AP9300578A0 (en) Sulfonamide derivatives of benzenefused, hydroxy substituted cycloalkyl and heterocyclic ring compounds.
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
ATE151405T1 (de) (7s)-7-(2r)-2-(3-chlorophenyl)-2-hydoxyethylami o-5,6,7,8-tetrahydronaphtalen-2-yloxy essigsäure, ihre pharmazeutisch akzeptablen salze, mit beta-3-adrenergischer agonistischer aktivität und diese enthaltende pharmazeutische zusammensetzungen
SE8305917D0 (sv) Mellanprodukter for anvendning vid framstellning av hexahydro-gamma-karbolinforeningar
ATE152708T1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino- tetralinderivate
GB1085672A (en) Substituted phthalazines
SE8302411L (sv) Kondenserade cykloalifatiska derivat av substituerade pyrido(1,2-a)pyrimidiner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 587723

Country of ref document: ES